{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-052081","form_type":"8-K","ticker":"MRK","cik":"0000310158","company_name":"Merck & Co., Inc.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.543625+00:00","generated_at":"2026-05-15T01:15:00.476351+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Merck reports Q1 GAAP loss per share of $1.72 on $16.3B sales; narrows and raises full-year guidance","bullets":["GAAP EPS loss of $1.72; Non-GAAP EPS loss of $1.28, both include $3.62/share charge for Cidara acquisition.","Total sales $16.3B, +5% YoY; KEYTRUDA sales $8.0B (+12%), WINREVAIR $525M (+88%).","Full-year 2026 sales guidance raised to $65.8B-$67.0B; Non-GAAP EPS guidance raised to $5.04-$5.16.","Announced agreement to acquire Terns Pharmaceuticals; one-time charge ~$5.8B (~$2.35/share) not in guidance.","Animal Health sales $1.8B (+13%); multiple regulatory approvals including IDVYNSO for HIV."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-052081","json":"https://secwatch.observer/filing/0001104659-26-052081.json","markdown":"https://secwatch.observer/filing/0001104659-26-052081.md","text":"https://secwatch.observer/filing/0001104659-26-052081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/0001104659-26-052081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:15:00.476351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6872b0c09b01c753aca4761532475d3c466960ef","claim":"Merck & Co., Inc. reported first quarter of 2026 results: revenue $16,286, net income (4,240), EPS (1.72). Guidance raised.","evidence_excerpt":"First Quarter $ in millions, except EPS amounts 2026 2025 Change Change Ex- Exchange Sales $ 16,286 $ 15,529 5 % 3 % GAAP net (loss) income 2 (4,240 ) 5,079 N/M N/M Non-GAAP net (loss) income that excludes certain items 2,3* (3,156 ) 5,611 N/M N/M GAAP EPS (1.72 ) 2.01 N/M N/M","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/0001104659-26-052081-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2026"},{"label":"Revenue","value":"$16,286"},{"label":"Net income","value":"(4,240)"},{"label":"EPS","value":"(1.72)"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}